Dr. Gary C. Steven, M.D.
Allergy & Immunology (Allergy Physician)
8585 W Forest Home Ave, Suite 200
Greenfield, WI 53228
Who else practices at this address →
Milwaukee County includes primary care (32% of residents) and mental health (34% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Medical College of Wisconsin (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 189
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Medical College of Wisconsin
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
WI license 33574020 -
Specialist
WI license 33574020
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Allergy Asthma and Sinus Center Sc (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 189
- Services billed
- 5,830
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 766 | 36 |
| Professional service for multiple injections of allergen | 518 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 80 | 55 |
| Established patient office or other outpatient visit, 20-29 minutes | 74 | 71 |
| Test to measure the level of nitric oxide gas | 29 | 25 |
| Test to measure expiratory airflow and volume | 28 | 25 |
| New patient office or other outpatient visit, 30-44 minutes | 21 | 21 |
| Administration of influenza virus vaccine | 13 | 13 |
| Influenza vaccine split virus, preservative free | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Greenfield, WI | 124 |
| Fluticasone Propionate Other prescribers in Greenfield, WI | 118 |
| Azelastine Hcl Other prescribers in Greenfield, WI | 108 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Greenfield, WI | 90 |
| Omeprazole Other prescribers in Greenfield, WI | 75 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Greenfield, WI | 74 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Greenfield, WI | 65 |
| Ipratropium Bromide Other prescribers in Greenfield, WI | 65 |
| Montelukast Sodium Other prescribers in Greenfield, WI | 62 |
| Esomeprazole Magnesium Other prescribers in Greenfield, WI | 55 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 112 payments worth $14,396 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $11,386 |
|---|---|
| GlaxoSmithKline, LLC. | $1,157 |
| Genzyme Corporation | $462 |
| Novartis Pharmaceuticals Corporation | $280 |
| Optinose US, Inc. | $186 |
| Regeneron Healthcare Solutions, Inc. | $154 |
| Verona Pharma, Inc. | $151 |
| Genentech USA, Inc. | $119 |
| Compensation for services other than consulting (speaking, faculty) | $9,300 |
|---|---|
| Food and Beverage | $4,016 |
| Travel and Lodging | $946 |
| Education | $133 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $3,700 |
| AstraZeneca Pharmaceuticals LP Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $3,700 |
| AstraZeneca Pharmaceuticals LP Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Mar 27, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Rockford, IL · in-kind Company’s descriptionSpeaker Expenses | $747 |
| AstraZeneca Pharmaceuticals LP Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP May 29, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $250 |
| Regeneron Healthcare Solutions, Inc. Sep 24, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $99.26 |
| AstraZeneca Pharmaceuticals LP May 23, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $71.74 |
| AstraZeneca Pharmaceuticals LP Jul 9, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $51.00 |
| AstraZeneca Pharmaceuticals LP May 23, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $37.40 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Sep 24, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $99.26 |
| Amgen Inc. Sep 3, 2025 | Education in-kind | $34.00 |
| AstraZeneca Pharmaceuticals LP Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $1,400 |
| AstraZeneca Pharmaceuticals LP Jul 9, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $51.00 |
| AstraZeneca Pharmaceuticals LP Jul 9, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $20.74 |
| AstraZeneca Pharmaceuticals LP Jun 30, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Waukesha, WI · in-kind Company’s descriptionSpeaker Expenses | $18.20 |
| AstraZeneca Pharmaceuticals LP May 29, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP May 23, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $71.74 |
| AstraZeneca Pharmaceuticals LP May 23, 2025 | Travel and Lodging travel to Denver, CO Company’s descriptionResearch Related Service | $37.40 |
| AstraZeneca Pharmaceuticals LP Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $3,700 |
| AstraZeneca Pharmaceuticals LP Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $3,700 |
| AstraZeneca Pharmaceuticals LP Mar 27, 2025 | Travel and Lodging AIRSUPRA · Respiratory · travel to Rockford, IL · in-kind Company’s descriptionSpeaker Expenses | $747 |
| AstraZeneca Pharmaceuticals LP Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) AIRSUPRA · Respiratory Company’s descriptionSpeaker Fee | $250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 8 companies. The companies reported $1,269,262 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
AstraZeneca Pharmaceuticals LP - A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label…
AstraZeneca Pharmaceuticals LP - A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Eli Lilly and Company · Active, not recruiting · NCT06339008 - Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630
AstraZeneca Pharmaceuticals LP - A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (…
Novartis Pharmaceuticals Corporation - Ph III OLE of Astegolimab in COPD
Genentech, Inc. - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma
AstraZeneca Pharmaceuticals LP - A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Teva Pharmaceuticals USA, Inc. - A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in…
Teva Pharmaceuticals USA, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.